Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 12/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18004370 | 0.86 | KIF11 (0.40) | NLRP3KDM1A | |
| SCHEMBL18004266 | 0.84 | CTSS (0.36) | NLRP3 | |
| SCHEMBL18004153 | 0.83 | SMN1; SMN2 (0.41) | POLB | |
| SCHEMBL18004367 | 0.81 | CNR1 (0.42) | L3MBTL1 | |
| SCHEMBL16398471 | 0.81 | CYP2A6 (0.34) | TOP1RETPOLBL3MBTL1KDM1A | |
| SCHEMBL18004997 | 0.80 | NPBWR1 (0.39) | LRRK2NLRP3 | |
| SCHEMBL18004259 | 0.79 | TRPA1 (0.40) | KDM1A | |
| SCHEMBL18004147 | 0.79 | PTGDR2 (0.44) | L3MBTL1KDM1A | |
| SCHEMBL18003480 | 0.78 | ABCC8 (0.44) | NLRP3 | |
| SCHEMBL18003772 | 0.78 | AR (0.35) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | TOP1 2566/4885IDH2 26/4885RET 1961/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | TOP1 2566/4885IDH2 26/4885RET 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.